source
- Moderna and Merck's mRNA melanoma vaccine cuts recurrence risk by 42% in trialA large Phase 2 trial led by Moderna and Merck showed that their personalized mRNA vaccine, intismeran autogene, lowered the chance of melanoma returning by 42% compared with standard therapy. The…
- Moderna and Merck prepare to unveil cancer vaccine data at ESMO CongressAdam Feuerstein reports from the European Society for Medical Oncology meeting in Madrid that the long‑awaited data from the Moderna‑Merck cancer vaccine partnership will be presented in the coming…